Headache News and Research

Latest Headache News and Research

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Experts develop tools to educate people about health risks associated with global travel

Experts develop tools to educate people about health risks associated with global travel

Phase III study suggests CYCLOSET tablets improve glycemic control

Phase III study suggests CYCLOSET tablets improve glycemic control

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Workers unwilling to disclose work related stress: Survey

Workers unwilling to disclose work related stress: Survey

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

Merck's boceprevir improves SVR rate in adults with chronic hepatitis C virus genotype 1 infection

NeurAxon’s NXN-188 compound effective for acute migraine treatment

NeurAxon’s NXN-188 compound effective for acute migraine treatment

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.